---
title: "Darzalex (daratumumab) in multiple myeloma: Clinical trials questions"
description: "Clinical trials questions on Darzalex (daratumumab) in multiple myeloma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results and Subgroup results. Questions: How much does Darzalex (DRd) delay myeloma progression in patients ineligible for transplant (MAIA)? Do patients live longer on Darzalex with lenalidomide and dexamethasone (MAIA)? What response and MRD-negativity rates did Darzalex (DRd) achieve in MAIA? What MRD-negativity and complete response rates did Darzalex Faspro with VRd achieve (CEPHEUS)? 8 further questions follow. 12 questions quoted from 9 sources."
canonical: "https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Darzalex (daratumumab) in multiple myeloma: Clinical trials questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Darzalex](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf), [Darzalex Faspro](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf)

Questions that apply to every indication of Darzalex are on [Darzalex (daratumumab), all indications](https://www.evicenter.com/medical-information/darzalex).

## Study results

<a id="darzalex-maia-pfs"></a>

### How much does Darzalex (DRd) delay myeloma progression in patients ineligible for transplant (MAIA)?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)

> “MAIA (NCT02252172), an open-label, randomized, active-controlled trial, 
> compared treatment with DARZALEX 16 mg/kg in combination with lenalidomide 
> and low-dose dexamethasone (DRd) to treatment with lenalidomide and low-
> dose dexamethasone (Rd) in patients with newly diagnosed multiple myeloma 
> ineligible for autologous stem cell transplant. Lenalidomide (25 mg once daily 
> orally on Days 1-21 of repeated 28-day [4-week] cycles) was given with low 
> dose oral or intravenous dexamethasone 40 mg/week (or a reduced dose 
> of 20 mg/week for patients >75 years or body mass index [BMI] <18.5). On 
> DARZALEX infusion days, the dexamethasone dose was given as a pre-infusion 
> medication. Treatment was continued in both arms until disease progression 
> or unacceptable toxicity.”

Source: [DARZALEX: DARZALEX®, page 11, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=11)

> “A total of 737 patients were randomized: 368 to the DRd arm and 369 to the 
> Rd arm. The baseline demographic and disease characteristics were similar 
> between the two treatment groups. The median age was 73 (range: 45-90) 
> years, with 44% of the patients ≥75 years of age.”

Source: [DARZALEX: DARZALEX®, page 11, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=11)

> “MAIA demonstrated an improvement in Progression Free Survival (PFS) in the 
> DRd arm as compared to the Rd arm; the median PFS had not been reached 
> in the DRd arm and was 31.9 months in the Rd arm (hazard ratio [HR]=0.56; 
> 95% CI: 0.43, 0.73; p<0.0001), representing 44% reduction in the risk of disease 
> progression or death in patients treated with DRd. After a median follow-up 
> of 64 months, the median PFS was 61.9 months (95% CI: 54.8, NE) in the DRd 
> arm and 34.4 months (95% CI: 29.6, 39.2) in the Rd arm.”

Source: [DARZALEX: DARZALEX®, page 11, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=11)

> “<sup>a</sup>	 PFS median follow-up of 28 months”

Source: [DARZALEX: DARZALEX®, page 11, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=11)

> “52.1% of patients in the DRd arm had not progressed at 60 months vs 29.6% of patients in the Rd arm (HR=0.55, 95% CI: 0.45-0.67)<sup>3</sup>”

Source: [DARZALEX: DRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/efficacy/#:~:text=52.1%25%20of%20patients%20in%20the,Rd%20arm%20%28HR%3D0.55%2C%2095%25%20CI%3A)

On the page, select: 64-month PFS

> “*Median follow-up was 64 months.<sup>1</sup>”

Source: [DARZALEX: DRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/efficacy/#:~:text=%2AMedian%20follow%2Dup%20was%2064)

On the page, select: 64-month PFS

Note: The 60-month progression-free rates and the hazard ratio of 0.55 are from the 64-month PFS tab of the MAIA efficacy page; the Prescribing Information reports the 64-month medians.

<a id="darzalex-maia-overall-survival"></a>

### Do patients live longer on Darzalex with lenalidomide and dexamethasone (MAIA)?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)

> “After a median follow-up of 56 months, MAIA demonstrated an improvement in 
> overall survival (OS) in the DRd arm as compared to the Rd arm (HR=0.68; 95% 
> CI: 0.53, 0.86; p=0.0013), representing a 32% reduction in the risk of death in 
> patients treated in the DRd arm. Median OS had not been reached for either arm.
> After a median follow-up of 89 months, the median OS was 90.3 months (95% 
> CI: 80.8, NE) in the DRd arm and 64.1 months (95% CI: 56.0, 70.8) in the Rd arm.”

Source: [DARZALEX: DARZALEX®, page 11, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=11)

> “66% of patients were still alive with DRd vs 53% with Rd alone at 60 months (DRd: 95% CI: 60.8-71.3; Rd: 95% CI: 47.2-58.6)<sup>4*</sup><sup>†</sup>”

Source: [DARZALEX: DRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/efficacy/#:~:text=66%25%20of%20patients%20were%20still,CI%3A%2060.8%2D71.3%3B%20Rd%3A%2095%25%20CI%3A)

> “*Median follow-up was 56.6 months in the DRd group (IQR: 53.0-60.1 months) and 55.9 months in the Rd group (IQR: 52.5-59.4 months).<sup>4</sup>”

Source: [DARZALEX: DRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/efficacy/#:~:text=%2AMedian%20follow%2Dup%20was%2056.6%20months,the%20Rd%20group%20%28IQR%3A%2052.5%2D59.4)

> “53.1% of patients in the DRd arm were still alive at 89 months vs 39.3% of patients in the Rd arm (HR=0.67; 95% CI: 0.55-0.82)”

Source: [DARZALEX: DRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/efficacy/#:~:text=53.1%25%20of%20patients%20in%20the,arm%20%28HR%3D0.67%3B%2095%25%20CI%3A%200.55%2D0.82%29)

On the page, select: 89-month OS

> “*Median follow-up was 89.3 months (range: 0-102.2 months).<sup>5</sup>”

Source: [DARZALEX: DRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/efficacy/#:~:text=%2AMedian%20follow%2Dup%20was%2089.3%20months%20%28range%3A%200%2D102.2)

On the page, select: 89-month OS

Note: The 60-month and 89-month survival percentages are from the MAIA efficacy page (the 89-month figure from its 89-month OS tab); the Prescribing Information reports the 89-month medians.

<a id="darzalex-maia-response-mrd"></a>

### What response and MRD-negativity rates did Darzalex (DRd) achieve in MAIA?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)

> “Table 23: Additional Efficacy Results From MAIA<sup>a</sup>
> DRd (N=368)
> Rd (N=369)
> Overall response (sCR+CR+VGPR+PR) n(%)<sup>a</sup>
> 342 (92.9%)
> 300 (81.3%)
> p-value<sup>b</sup>
> <0.0001
> Stringent complete response (sCR) 
> 112 (30.4%)
> 46 (12.5%)
> Complete response (CR) 
> 63 (17.1%)
> 46 (12.5%)
> Very good partial response (VGPR) 
> 117 (31.8%)
> 104 (28.2%)
> Partial response (PR)
> 50 (13.6%)
> 104 (28.2%)”

Source: [DARZALEX: DARZALEX®, page 11, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=11)

> “Table 23: Additional Efficacy Results From MAIA<sup>a</sup> (continued)
> DRd (N=368)
> Rd (N=369)
> CR or better (sCR + CR)
> 175 (47.6%)
> 92 (24.9%)
> p-value<sup>b</sup>
> <0.0001
> VGPR or better (sCR + CR + VGPR)
> 292 (79.3%)
> 196 (53.1%)
> p-value<sup>b</sup>
> <0.0001
> MRD negativity rate<sup>a, c</sup> n(%)
> 89 (24.2%)
> 27 (7.3%)
> 95% CI (%)
> (19.9%, 28.9%)
> (4.9%, 10.5%)
> p-value<sup>d</sup>
> <0.0001
> MRD negativity rate in patients with CR or 
> better<sup>c</sup>
> Number of patients with CR or better
> N=175
> N=92
> MRD negativity rate n(%)
> 89 (50.9%)
> 27 (29.3%)
> 95% CI (%)
> (43.2%, 58.5%)
> (20.3%, 39.8%)
> DRd=daratumumab-lenalidomide-dexamethasone; Rd=lenalidomide-
> dexamethasone; MRD=minimal residual disease; CI=confidence interval
> <sup>a</sup>	 Based on intent-to-treat population.
> <sup>b</sup>	 p-value from Cochran Mantel-Haenszel Chi-Squared test.
> <sup>c</sup>	 Based on threshold of 10-5 using a next-generation sequencing assay 
> (clonoSEQ).
> <sup>d</sup> 	p-value from Fisher’s exact test.
> In responders, the median time to response was 1.05 months (range: 0.2 to 
> 12.1 months) in the DRd group and 1.05 months (range: 0.3 to 15.3 months) in 
> the Rd group. The median duration of response had not been reached in the 
> DRd group and was 34.7 months (95% CI: 30.8, not estimable) in the Rd group.”

Source: [DARZALEX: DARZALEX®, page 12, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=12)

Note: Table 23 columns are DRd (N=368) and Rd (N=369), in that order. The MAIA efficacy page reports the response and MRD results at a median follow-up of 28 months.

<a id="darzalex-cepheus-mrd"></a>

### What MRD-negativity and complete response rates did Darzalex Faspro with VRd achieve (CEPHEUS)?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX FASPRO + bortezomib, lenalidomide, dexamethasone (DVRd) vs VRd (CEPHEUS)

> “The efficacy of DARZALEX FASPRO with bortezomib, lenalidomide and 
> dexamethasone (DARZALEX FASPRO-VRd) versus bortezomib, lenalidomide and 
> dexamethasone (VRd) was evaluated in CEPHEUS (NCT03652064), an open-label, 
> randomized, active-controlled trial in patients with newly diagnosed multiple 
> myeloma who were ineligible for ASCT or refused ASCT as initial therapy.”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “The effectiveness of DARZALEX FASPRO-VRd has not been established in 
> patients who refused ASCT as initial therapy.”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “The major efficacy outcome measures were overall minimal residual disease 
> (MRD) negativity rate and progression-free survival (PFS) by independent 
> review committee (IRC) based on IMWG response criteria.
> A total of 395 patients were randomized: 197 to the DARZALEX FASPRO-VRd 
> arm and 198 to the VRd arm. The median age was 70 years (range: 31 to 80); 
> 50% were male and 81% were White, 5% were Black or African American, 
> and 6% were Asian. Thirty-four percent had ISS Stage I, 38% had ISS Stage II, 
> and 28% had ISS Stage III disease. High-risk cytogenetics (presence of 
> del(17p), t(4;14), t(14,16)) were present in 13% of patients.
> The trial demonstrated a statistically significant improvement in overall MRD 
> negativity rate, PFS, CR or better rate, and sustained MRD negativity rate, as 
> shown in Table 29 and Figure 2.”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “Table 29: Efficacy Outcomes from CEPHEUS<sup>a,b</sup> 
> DARZALEX FASPRO-VRd 
> (N=197)
> VRd 
> (N=198)”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “MRD negativity rate n (%)<sup>f,g</sup>
> 103 (52.3%)
> 69 (34.8%)
> p-value<sup>h</sup>
> 0.0005
> Overall CR or better (sCR+CR) 
> n (%)<sup>f</sup>
> 150 (76.1%)
> 116 (58.6%)
> p-value<sup>h</sup>
> 0.0002”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “Table 29: Efficacy Outcomes from CEPHEUS<sup>a,b</sup> (continued)
> DARZALEX FASPRO-VRd 
> (N=197)
> VRd 
> (N=198)
> MRD negativity rate in 
> patients with CR or better<sup>f,i</sup>
> Number of patients with 
> CR or better
> n=150
> n=116
> MRD negativity rate n (%)
> 103 (68.7%)
> 69 (59.5%)
> 95% CI (%)<sup>j</sup>
> (60.6%, 76.0%)
> (50.0%, 68.5%)
> Sustained MRD negativity 
> rate n (%)<sup>c,k</sup>
> 84 (42.6%)
> 50 (25.3%)
> p-value<sup>l</sup>
> 0.0003
> Overall response 
> (sCR+CR+VGPR+PR) n(%)<sup>m</sup>
> 191 (97.0%)
> 185 (93.4%)
> Stringent Complete 
> Response (sCR)
> 128 (65.0%)
> 89 (44.9%)
> Complete response (CR)
> 32 (16.2%)
> 33 (16.7%)
> Very good partial 
> response (VGPR)
> 23 (11.7%)
> 49 (24.7%)
> Partial response (PR)
> 8 (4.1%)
> 14 (7.1%)”

Source: [DARZALEX: DARZALEX FASPRO®, page 16, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=16)

> “<sup>a</sup>	 Based on intent-to-treat population unless otherwise noted.
> <sup>b</sup>	 The hierarchical testing order in the CEPHEUS study was overall MRD 
> negativity rate followed by CR or better rate, PFS, and sustained MRD 
> negativity rate.
> <sup>c</sup>	 Interim analysis: Median follow-up of 39 months (cut-off date 08 September 2022).
> <sup>d</sup>	 Hazard ratio and 95% CI from a Cox proportional hazards model with 
> treatment as the sole explanatory variable and stratified with ISS staging 
> (I, II, III), and age/transplant eligibility (<70 years ineligible, or <70 years 
> and refusal to transplant, or ≥70 years) as randomized. A hazard ratio <1 
> indicates an advantage for D-VRd.
> <sup>e</sup>	 p-value is based on the log-rank test stratified with ISS staging (I, II, III), 
> and age/transplant eligibility (<70 years ineligible, or <70 years and refusal 
> to transplant, or ≥70 years) as randomized.
> <sup>f</sup>	 Primary analysis: Median follow-up of 22 months (cut-off date 08 April 2021).
> <sup>g</sup>	 Patients achieved both MRD negativity (threshold of 10-5) and CR or better. 
> All MRD testing was performed with a next-generation sequencing assay 
> (clonoSEQ).
> <sup>h</sup>	 p-value from Cochran Mantel-Haenszel Chi-Squared test.
> <sup>i</sup>	 Patients achieving MRD negativity (threshold of 10-5) among only patients 
> achieving a response of CR or better.
> <sup>j</sup>	 Exact 95% confidence interval.
> <sup>k</sup>	 Sustained MRD negativity is defined as confirmed MRD negative status at two 
> examinations at least 1 year apart without MRD positive status in between.
> <sup>l</sup>	 p-value from Fisher’s exact test. 
> <sup>m</sup>	Final analysis: Median follow-up of 59 months (cut-off date 07 May 2024).”

Source: [DARZALEX: DARZALEX FASPRO®, page 16, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=16)

Note: Table 29 columns are DARZALEX FASPRO-VRd (N=197) and VRd (N=198), in that order. Footnotes f, c, and m date each row to the primary (22-month), interim (39-month), or final (59-month) analysis.

<a id="darzalex-cepheus-pfs"></a>

### Does Darzalex Faspro with VRd delay myeloma progression in transplant-ineligible patients (CEPHEUS)?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX FASPRO + bortezomib, lenalidomide, dexamethasone (DVRd) vs VRd (CEPHEUS)

> “The efficacy of DARZALEX FASPRO with bortezomib, lenalidomide and 
> dexamethasone (DARZALEX FASPRO-VRd) versus bortezomib, lenalidomide and 
> dexamethasone (VRd) was evaluated in CEPHEUS (NCT03652064), an open-label, 
> randomized, active-controlled trial in patients with newly diagnosed multiple 
> myeloma who were ineligible for ASCT or refused ASCT as initial therapy.”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “Table 29: Efficacy Outcomes from CEPHEUS<sup>a,b</sup> 
> DARZALEX FASPRO-VRd 
> (N=197)
> VRd 
> (N=198)”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “PFS based on IRC<sup>c</sup>
> Number of events, n (%)
> 46 (23.4%)
> 68 (34.3%)
> Median, months with 
> 95% CI
> NR (NE, NE)
> NR (NE, NE)
> Hazard ratio with 95% CI<sup>d</sup>
> 0.60 (0.41, 0.88)
> p-value<sup>e</sup>
> 0.0078”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “<sup>a</sup>	 Based on intent-to-treat population unless otherwise noted.
> <sup>b</sup>	 The hierarchical testing order in the CEPHEUS study was overall MRD 
> negativity rate followed by CR or better rate, PFS, and sustained MRD 
> negativity rate.
> <sup>c</sup>	 Interim analysis: Median follow-up of 39 months (cut-off date 08 September 2022).
> <sup>d</sup>	 Hazard ratio and 95% CI from a Cox proportional hazards model with 
> treatment as the sole explanatory variable and stratified with ISS staging 
> (I, II, III), and age/transplant eligibility (<70 years ineligible, or <70 years 
> and refusal to transplant, or ≥70 years) as randomized. A hazard ratio <1 
> indicates an advantage for D-VRd.
> <sup>e</sup>	 p-value is based on the log-rank test stratified with ISS staging (I, II, III), 
> and age/transplant eligibility (<70 years ineligible, or <70 years and refusal 
> to transplant, or ≥70 years) as randomized.
> <sup>f</sup>	 Primary analysis: Median follow-up of 22 months (cut-off date 08 April 2021).
> <sup>g</sup>	 Patients achieved both MRD negativity (threshold of 10-5) and CR or better. 
> All MRD testing was performed with a next-generation sequencing assay 
> (clonoSEQ).
> <sup>h</sup>	 p-value from Cochran Mantel-Haenszel Chi-Squared test.
> <sup>i</sup>	 Patients achieving MRD negativity (threshold of 10-5) among only patients 
> achieving a response of CR or better.
> <sup>j</sup>	 Exact 95% confidence interval.
> <sup>k</sup>	 Sustained MRD negativity is defined as confirmed MRD negative status at two 
> examinations at least 1 year apart without MRD positive status in between.
> <sup>l</sup>	 p-value from Fisher’s exact test. 
> <sup>m</sup>	Final analysis: Median follow-up of 59 months (cut-off date 07 May 2024).”

Source: [DARZALEX: DARZALEX FASPRO®, page 16, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=16)

> “The median PFS has not been reached in either arm<sup>4</sup>”

Source: [DARZALEX: CEPHEUS DVRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/quad/cepheus/efficacy/#:~:text=The%20median%20PFS%20has%20not%20been%20reached%20in%20either)

Note: Table 29 columns are DARZALEX FASPRO-VRd (N=197) and VRd (N=198), in that order. The CEPHEUS efficacy page also shows a 59-month final analysis as a graphic.

<a id="darzalex-perseus-pfs"></a>

### Does Darzalex Faspro with VRd delay myeloma progression in transplant-eligible patients (PERSEUS)?

Applies to: Newly diagnosed multiple myeloma, eligible for autologous stem cell transplant: DARZALEX FASPRO + VRd induction and consolidation vs VRd (PERSEUS)

> “The efficacy of DARZALEX FASPRO with bortezomib, lenalidomide and 
> dexamethasone (DARZALEX FASPRO-VRd) during induction and consolidation 
> was evaluated in PERSEUS (NCT03710603), an open-label, randomized, active-
> controlled trial in patients with newly diagnosed multiple myeloma eligible for 
> ASCT. Enrollment was limited to patients 70 years of age and younger.”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “The major efficacy outcome measure was progression-free survival (PFS) 
> by independent review committee (IRC) based on IMWG response criteria.
> A total of 709 patients were randomized: 355 to the DARZALEX FASPRO-VRd 
> arm and 354 to the VRd arm. The median age was 60 years (range: 31 to 70); 
> 59% were male, 92% were White, 1% were Black or African American, and 
> 1% were Asian. Fifty-one percent had ISS Stage I, 34% had ISS Stage II, 15% 
> had ISS Stage III disease. High-risk cytogenetics (presence of del(17p), t(4;14), 
> t(14,16)) were present in 22% of patients.
> PERSEUS demonstrated an improvement in PFS in the DARZALEX FASPRO-VRd 
> arm as compared to the VRd arm; the median PFS had not been reached in 
> either arm. Treatment with DARZALEX FASPRO-VRd resulted in a reduction 
> in the risk of disease progression or death by 60% compared to VRd alone 
> (HR [95% CI]: 0.40 [0.29, 0.57]; p-value < 0.0001).”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “Following consolidation, 
> patients received an investigational treatment regimen for maintenance that 
> included DARZALEX FASPRO in combination with lenalidomide or lenalidomide 
> alone. The trial was not designed to isolate the effect of DARZALEX FASPRO 
> in the maintenance phase of treatment. The efficacy of DARZALEX FASPRO 
> in combination with lenalidomide for maintenance has not been established.”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “*Median follow-up was 47.5 months in the DVRd and VRd groups (range: 0-54.4 months).<sup>2</sup>”

Source: [DARZALEX: DVRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/quad/perseus/efficacy/#:~:text=%2AMedian%20follow%2Dup%20was%2047.5%20months,and%20VRd%20groups%20%28range%3A%200%2D54.4)

Note: The median follow-up of 47.5 months is from the PERSEUS efficacy page of the Darzalex HCP site.

<a id="darzalex-perseus-response-mrd"></a>

### What response and MRD-negativity rates did Darzalex Faspro with VRd achieve (PERSEUS)?

Applies to: Newly diagnosed multiple myeloma, eligible for autologous stem cell transplant: DARZALEX FASPRO + VRd induction and consolidation vs VRd (PERSEUS)

> “Table 28: Efficacy Results through End of Consolidation from PERSEUS 
> DARZALEX FASPRO-VRd 
> (n=355)
> VRd (n=354)
> Overall response 
> (sCR+CR+VGPR+PR), n (%)<sup>a</sup>
> 338 (95.2%)
> 326 (92.1%)
> Stringent complete 
> response (sCR)
> 67 (18.9%)
> 46 (13.0%)
> Complete response (CR)
> 91 (25.6%)
> 77 (21.8%)
> Very good partial 
> response (VGPR)
> 165 (46.5%)
> 168 (47.5%)
> Partial response (PR)
> 15 (4.2%)
> 35 (9.9%)
> CR or better (sCR+CR)<sup>a</sup>, n (%)
> 158 (44.5%)
> 123 (34.7%)
> 95% CI (%)<sup>b</sup>
> (39.3%, 49.9%)
> (29.8%, 40.0%)
> MRD negativity rate<sup>a,c,d</sup>, n (%)
> 204 (57.5%)
> 115 (32.5%)
> 95% CI (%)<sup>b</sup>
> (52.1%, 62.7%)
> (27.6%, 37.6%)
> MRD negativity rate in 
> patients with CR or better<sup>c,e</sup>
> Number of patients with 
> CR or better
> n=158
> n=123
> MRD negativity rate n (%)
> 121 (76.6%)
> 72 (58.5%)
> 95% CI (%)<sup>b</sup>
> (69.2%, 82.9%)
> (49.3%, 67.3%)
> VRd = bortezomib-lenalidomide-dexamethasone; MRD=minimal residual 
> disease; CI=confidence interval
> <sup>a</sup>	 Based on intent-to-treat population
> <sup>b</sup>	 Exact 95% confidence interval
> <sup>c</sup>	 Based on threshold of 10-5 using a next-generation sequencing assay (clonoSEQ)
> <sup>d</sup>	 Patients achieved both MRD negativity (threshold of 10-5) and response of 
> CR or better
> <sup>e</sup>	 Based on patients with CR or better response by the end of consolidation”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “The median time to reach post-transplant consolidation was 9.9 months in the DVRd arm (range: 0.5-18.5 months).<sup>1</sup>”

Source: [DARZALEX: DVRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/quad/perseus/efficacy/#:~:text=The%20median%20time%20to%20reach,the%20DVRd%20arm%20%28range%3A%200.5%2D18.5)

Note: Table 28 columns are DARZALEX FASPRO-VRd (n=355) and VRd (n=354), in that order; results are through the end of post-transplant consolidation.

<a id="darzalex-aquila-smoldering"></a>

### How much does Darzalex Faspro lower the risk of progression in high-risk smoldering myeloma (AQUILA)?

Applies to: High-risk smoldering multiple myeloma: DARZALEX FASPRO monotherapy vs active monitoring (AQUILA)

> “51%”

Source: [DARZALEX: DARZALEX FASPRO® monotherapy is the first and only FDA-approved treatment in high-risk smoldering multiple myeloma1, page 1, captured 2026-11-12](https://www.darzalexhcp.com/pdfs/aquila.pdf#page=1)

> “reduction in the risk of disease  
> progression or death with  
> DARZALEX FASPRO<sup>®</sup>  
> vs active monitoring (HR=0.49;  
> 95% CI: 0.36-0.67; P<0.0001).<sup>1</sup>”

Source: [DARZALEX: DARZALEX FASPRO® monotherapy is the first and only FDA-approved treatment in high-risk smoldering multiple myeloma1, page 1, captured 2026-11-12](https://www.darzalexhcp.com/pdfs/aquila.pdf#page=1)

> “Study design<sup>1,2</sup>: AQUILA, a phase 3, open-label, multicenter, randomized trial evaluated the efficacy and safety of DARZALEX FASPRO<sup>®</sup> 
> monotherapy (n=194) vs active monitoring (n=196) in adult patients with high-risk smoldering multiple myeloma. 
> The median patient age was 64 years (range, 31-86 years). Forty-one percent of patients had 2 or more of the following criteria  
> for high-risk smoldering multiple myeloma: serum monoclonal protein level >2 g/dL, involved-to-uninvolved serum-free light chain  
> ratio >20, and bone marrow plasma cells >20%. DARZALEX FASPRO<sup>®</sup> is only indicated for patients with high-risk smoldering  
> multiple myeloma. It is not indicated for other risk categories.”

Source: [DARZALEX: DARZALEX FASPRO® monotherapy is the first and only FDA-approved treatment in high-risk smoldering multiple myeloma1, page 1, captured 2026-11-12](https://www.darzalexhcp.com/pdfs/aquila.pdf#page=1)

> “The primary endpoint was progression-free survival by independent review committee, defined as the diagnosis of multiple myeloma 
> based on the International Myeloma Working Group diagnostic criteria, or death.”

Source: [DARZALEX: DARZALEX FASPRO® monotherapy is the first and only FDA-approved treatment in high-risk smoldering multiple myeloma1, page 1, captured 2026-11-12](https://www.darzalexhcp.com/pdfs/aquila.pdf#page=1)

> “Table 35: Efficacy Results from AQUILA<sup>a</sup>
> DARZALEX 
> FASPRO 
> (n=194)
> Active 
> Monitoring 
> (n=196)
> Overall response (sCR+CR+VGPR+PR), n (%)a 123 (63.4%)
> 2 (1.0%)
> Stringent complete response (sCR)
> 7 (3.6%)
> 0
> Complete response (CR)
> 10 (5.2%)
> 0
> Very good partial response (VGPR)
> 41 (21.1%)
> 1 (0.5%)
> Partial response (PR)
> 65 (33.5%)
> 1 (0.5%)
> <sup>a</sup>	 Based on intent-to-treat population per investigator assessment”

Source: [DARZALEX: DARZALEX FASPRO®, page 18, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=18)

Note: The hazard ratio is from the AQUILA summary that the Darzalex HCP site links. Table 35 columns are DARZALEX FASPRO (n=194) and active monitoring (n=196), in that order.

## Subgroup results

<a id="darzalex-perseus-high-risk-cytogenetics"></a>

### Does Darzalex Faspro with VRd lower progression risk in high-risk cytogenetics (PERSEUS post hoc)?

Applies to: Newly diagnosed multiple myeloma, eligible for autologous stem cell transplant: DVRd vs VRd, post hoc cytogenetic subgroup analysis of PERSEUS

> “IMPORTANT: The cytogenetic subgroup analyses are not included in the Prescribing Information for DARZALEX FASPRO<sup>®</sup> and have not been evaluated by the FDA. These analyses were conducted post hoc, and there are insufficient numbers of patients per subgroup to make conclusions of efficacy among the subgroups.”

Source: [DARZALEX: DVRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/quad/perseus/efficacy/#:~:text=IMPORTANT%3A%20The%20cytogenetic%20subgroup%20analyses,of%20efficacy%20among%20the%20subgroups.)

> “High cytogenetic risk is defined as having at least 1 out of the following 5 abnormalities: del(17p), t(4;14), t(14;16), gain(1q21), or amp(1q21).<sup>4</sup>”

Source: [DARZALEX: DVRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/quad/perseus/efficacy/#:~:text=High%20cytogenetic%20risk%20is%20defined%20as%20having%20at%20least%201%20out%20of,-the%20following%205)

> “47
> %
> reduction in the risk
>
> for disease progression or death with DARZALEX FASPRO<sup>®</sup> + VRd vs VRd alone (HR=0.53; 95% CI: 0.35-0.81)<sup>5</sup>*”

Source: [DARZALEX: DVRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/quad/perseus/efficacy/#:~:text=the%20revised%20definition-,47,VRd%20alone%20%28HR%3D0.53%3B%2095%25%20CI%3A)

> “In a subgroup analysis of patients with high cytogenetic risk based on the protocol definition: 41% risk reduction for disease progression or death with DARZALEX FASPRO<sup>®</sup> + VRd vs VRd alone (HR=0.59; 95% CI: 0.36-0.99)<sup>5</sup>*”

Source: [DARZALEX: DVRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/quad/perseus/efficacy/#:~:text=In%20a%20subgroup%20analysis%20of,VRd%20alone%20%28HR%3D0.59%3B%2095%25%20CI%3A)

> “*Median follow-up was 47.5 months.<sup>5</sup>”

Source: [DARZALEX: DVRd Efficacy, captured 2026-11-12](https://www.darzalexhcp.com/quad/perseus/efficacy/#:~:text=insert%3A%20t%3Dtranslocation%3B%20VRd%3Dbortezomib%20%28V%29%20%2B%20lenalidomide%20%28R%29%20%2B%20dexamethasone%20%28d%29.-,%2AMedian%20follow%2Dup%20was%2047.5%20months.5)

Note: This is a post hoc analysis; results include the investigational DARZALEX FASPRO + lenalidomide maintenance phase.

<a id="darzalex-maia-age-80-and-older"></a>

### Does Darzalex (DRd) work in patients 80 years and older (MAIA post hoc)?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DRd vs Rd, post hoc subgroup analyses of MAIA

> “The age-specific subgroup analyses were conducted post hoc, are not included in the Prescribing Information for DARZALEX<sup>®</sup>, and have not been evaluated by the FDA; no conclusions should be drawn.”

Source: [DARZALEX: DRd Age Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/age/#:~:text=The%20age%2Dspecific%20subgroup%20analyses%20were,no%20conclusions%20should%20be%20drawn.)

> “The MAIA trial reported updated safety and efficacy data from age subgroups (<70, ≥70 to <75, ≥75, and ≥80 years) with a median follow-up of 64.5 months (range, 0-77.6).<sup>3</sup>”

Source: [DARZALEX: DRd Age Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/age/#:~:text=The%20MAIA%20trial%20reported%20updated,follow%2Dup%20of%2064.5%20months%20%28range%2C)

> “mPFS 52.2 months for DRd vs 30.4 months for Rd (HR=0.48; 95% CI: 0.31-0.76)<sup>3</sup>”

Source: [DARZALEX: DRd Age Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/age/#:~:text=mPFS%2052.2%20months%20for%20DRd,for%20Rd%20%28HR%3D0.48%3B%2095%25%20CI%3A)

> “ORRs, rates of ≥CR, and rates of ≥VGPR were higher for DARZALEX<sup>®</sup> + Rd vs Rd alone across all age subgroups. In those ≥80 years:
>
> The ORR in the DRd group was 89.4% vs 77.5% in the Rd alone group
> The ≥CR rate in the DRd group was 43.9% vs 21.1% in the Rd alone group
> The ≥VGPR rate in the DRd group was 75.8% vs 43.7% in the Rd alone group”

Source: [DARZALEX: DRd Age Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/age/#:~:text=ORRs%2C%20rates%20of%20%E2%89%A5CR%2C%20and,43.7%25%20in%20the%20Rd%20alone%20group)

> “Serious TEAEs occurred in 81.5% of patients ≥80 years of age in the DRd arm and 82.9% in the Rd arm, with pneumonia being the most common (24.6% and 8.6%, respectively)
>
> TEAEs that led to treatment discontinuation occurred in 6.2% of patients ≥80 years of age in the DRd arm and 20.0% in the Rd arm
>
> TEAEs with an outcome of death occurred in 12.3% of patients ≥80 years of age in the DRd arm and 11.4% in the Rd arm”

Source: [DARZALEX: DRd Age Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/age/#:~:text=Serious%20TEAEs%20occurred%20in%2081.5%25,11.4%25%20in%20the%20Rd%20arm)

<a id="darzalex-maia-frail-patients"></a>

### Does Darzalex (DRd) work in frail patients (MAIA post hoc)?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DRd vs Rd, post hoc subgroup analyses of MAIA

> “This analysis is not included in the Prescribing Information for DARZALEX<sup>®</sup>. This analysis was conducted post hoc, and there are insufficient numbers of patients per subgroup to make definitive conclusions of efficacy among the subgroups.”

Source: [DARZALEX: DRd Frailty Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/frailty/#:~:text=This%20analysis%20is%20not%20included,of%20efficacy%20among%20the%20subgroups.)

> “The median age in frail subgroup was 77 years (range: 57-90 years), with 88% of patients having ECOG PS ≥1<sup>1</sup>”

Source: [DARZALEX: DRd Frailty Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/frailty/#:~:text=The%20median%20age%20in%20frail,of%20patients%20having%20ECOG%20PS)

> “Frailty assessment was performed retrospectively using age, CCI, and baseline ECOG PS<sup>1</sup>”

Source: [DARZALEX: DRd Frailty Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/frailty/#:~:text=Frailty%20assessment%20was%20performed%20retrospectively%20using%20age%2C%20CCI%2C%20and%20baseline%20ECOG)

> “61.5% of patients had not progressed with frontline DARZALEX<sup>®</sup> + Rd vs 39.5% of patients with Rd alone<sup>1</sup>*”

Source: [DARZALEX: DRd Frailty Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/frailty/#:~:text=61.5%25%20of%20patients%20had%20not,39.5%25%20of%20patients%20with%20Rd)

> “In frail patients, the risk reduction for disease progression or death was 38% with DRd vs Rd alone (HR=0.62; 95% CI: 0.45-0.85)<sup>1</sup>”

Source: [DARZALEX: DRd Frailty Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/frailty/#:~:text=In%20frail%20patients%2C%20the%20risk,Rd%20alone%20%28HR%3D0.62%3B%2095%25%20CI%3A)

> “*Median follow-up was 36.4 months.<sup>1</sup>”

Source: [DARZALEX: DRd Frailty Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/frailty/#:~:text=%2AMedian%20follow%2Dup%20was%2036.4)

<a id="darzalex-maia-high-risk-cytogenetics"></a>

### Does Darzalex (DRd) work in patients with high-risk cytogenetics (MAIA post hoc)?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DRd vs Rd, post hoc subgroup analyses of MAIA

> “This analysis is not included in the Prescribing Information for DARZALEX<sup>®</sup>. This analysis was conducted post hoc, and there are insufficient numbers of patients per subgroup to make definitive conclusions of efficacy among the subgroups.”

Source: [DARZALEX: DRd High-Risk Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/high-risk/#:~:text=This%20analysis%20is%20not%20included,of%20efficacy%20among%20the%20subgroups.)

> “Revised high-risk cytogenetics defined as having at least 1 of the following 6 abnormalities: t[4;14], t[14;16], del[17p], t[14;20], gain[1q21], or amp[1q21].<sup>1</sup>”

Source: [DARZALEX: DRd High-Risk Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/high-risk/#:~:text=Revised%20high%2Drisk%20cytogenetics%20defined%20as,t%5B14%3B16%5D%2C%20del%5B17p%5D%2C%20t%5B14%3B20%5D%2C%20gain%5B1q21%5D%2C%20or)

> “Median PFS was 61.4 months with DRd vs 31.2 months with Rd alone among patients with 1 high-risk cytogenetic abnormality<sup>1</sup>*”

Source: [DARZALEX: DRd High-Risk Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/high-risk/#:~:text=Median%20PFS%20was%2061.4%20months,patients%20with%201%20high%2Drisk%20cytogenetic)

> “Among patients with revised standard cytogenetic risk (0 HRCA), median PFS was not reached with DRd vs 35.1 months with Rd alone (HR=0.50; 95% CI: 0.37-0.66)<sup>1</sup>*”

Source: [DARZALEX: DRd High-Risk Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/high-risk/#:~:text=Among%20patients%20with%20revised%20standard,Rd%20alone%20%28HR%3D0.50%3B%2095%25%20CI%3A)

> “Median PFS was 24.9 months with frontline DRd vs 24.0 months with Rd alone among patients
> with ≥2 high-risk cytogenetic abnormalities<sup>1</sup>*”

Source: [DARZALEX: DRd High-Risk Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/high-risk/#:~:text=Median%20PFS%20was%2024.9%20months,with%20%E2%89%A52%20high%2Drisk%20cytogenetic)

On the page, select: ≥2 HRCAs

> “*Median follow-up was 64.5 months.<sup>1</sup>”

Source: [DARZALEX: DRd High-Risk Subgroup, captured 2026-11-12](https://www.darzalexhcp.com/triplet/patient-subgroups/high-risk/#:~:text=%2AMedian%20follow%2Dup%20was%2064.5)

## Related pages
- [Medical information: Darzalex (daratumumab): Multiple myeloma](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma)
- [Indication](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/guidelines)
